Journals / Turkish Journal of Gastroenterology / 2005 / Cilt: 16 - Sayı: 1

Lansoprazol, amoksisilin ve klaritromisin kombinasyonu H. pylori eradikasyonunda hala ilk basamak tedavi olarak kullanılabilir mi?

Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?

Pages
29–33
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The use of alternative treatment protocols or antibiotic susceptibility test before the treatment may be helpful in achieving successful eradication with first-line therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: To determine H. pylori eradication rate with lansoprazole-amoxicillin-clarithromycin treatment regimen, which is the most frequently used as first-line therapy, in the Kırıkkale region.
📊
Key Findings & Data:Methods: One hundred and five patients (44 male, 61 female) with H. pylori infection were included in the study.
💡
Conclusion & Impact:The use of alternative treatment protocols or antibiotic susceptibility test before the treatment may be helpful in achieving successful eradication with first-line therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Amoksisilin · Helicobacter enfeksiyonları · Klaritromisin

Abstract

Background/aims: To determine H. pylori eradication rate with lansoprazole-amoxicillin-clarithromycin treatment regimen, which is the most frequently used as first-line therapy, in the Kırıkkale region. Methods: One hundred and five patients (44 male, 61 female) with H. pylori infection were included in the study. Patients were divided into two groups based on the endoscopic findings: non-ulcer dyspepsia (n=84, 31 male, 53 female) and acute gastric or duodenal ulcer (n=21, 13 male, 8 female) groups. The diagnosis of H. pylori infection was confirmed if both the urease test and histological examination, which were performed on endoscopic biopsies, were positive. Lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg were given twice daily for 14 days to all patients. Endoscopic biopsies were repeated for the evaluation of eradication three months after the treatment. Results: Ninety-six patients completed the study. Eradication rates were found to be 45.8% (44 of 96) in all patients, 42.1% (32 of 76 patients) in the non-ulcer dyspepsia group and 60% (12 of 20 patients) in the gastric or duodenal ulcer group for per protocol analysis, and the difference between non-ulcer dyspepsia and gastric or duodenal ulcer groups was not statistically significant (p=0.208). Conclusions: Lansoprazole- amoxicillin-clarithromycin treatment regimen, the most frequently preferred regimen in H. pylori eradication, is ineffective in our region. The low eradication rates observed with lansoprazole- amoxicillin-clarithromycin, at least in our region, bring into question its use as a first-line therapy. The use of alternative treatment protocols or antibiotic susceptibility test before the treatment may be helpful in achieving successful eradication with first-line therapy.

Özet

Amaç: H. pylori eradikasyonunda en sık kullanılan tedavi rejimi olan lansoprazol-amoksisilin-klaritromisin ile Kırıkkale bölgesinde eradikasyon oranını belirlemek. Yöntem: H. pylori infeksiyonu tanısı konulan 105 hasta (44 erkek, 61 kadın) çalışmaya alındı. Endoskopik bulgulara göre hastalar iki gruba ayrı ldı: Non-ülser dispepsi (n=84, 31 erkek, 53 kadın) ve akut gastrik veya duodenal ülser (n=21, 13 erkek, 8 kadın) grupları. H. pylori infeksiyon tanısı endoskopik biyopsilerde yapılan üreaz testi ve histolojik incelemenin her ikisinin de pozitif olması ile konuldu. Tüm hastalara lansoprazol 30 mg, amoksisilin 1 g ve klaritromisin 500 mg günde iki kez 14 gün boyunca verildi. Eradikasyonun değerlendirilmesi için tedaviden üç ay sonra endoskopik biyopsiler tekrarlandı. Bulgular: Çalışmayı 96 hasta tamamladı. Per protokol analizde eradikasyon oranı tüm hastalarda %45,8 (44/96), NUD grubunda %42,1 (32/76), GDU grubunda ise %60 (12/20) olarak bulundu ve NUD ve GDU grupları arasındaki fark istatiksel olarak anlamlı değildi (p=0.208). Sonuç: Sonuç olarak H. Pylori tedavisinde en sık kullanılan tedavi protokolü olan lansoprazol-amoksisilin-klaritromisin protokolü bölgemizde başarısız bulunmuştur. Düşük eradikasyon oranları, en azından bizim bölgemizde, lansoprazol- amoksisilin-klaritromisin rejiminin ilk basamak tedavide kullanılabilirliğini sorgular hale gelmiştir. Alternatif tedavi protokollerinin kullanılması veya tedavi öncesi antibiyotik duyarlı lık testi yapılması ilk basamak tedavide başarılı eradikasyon elde etmek için yararlı olabilir.

🔖

Cite This Article

GÜLİTER, S., KELEŞ, H., ÖZKURT, Z. N., CENGİZ, D. U., KOLUKISA, E. (2005). Lansoprazol, amoksisilin ve klaritromisin kombinasyonu H. pylori eradikasyonunda hala ilk basamak tedavi olarak kullanılabilir mi?. Turkish Journal of Gastroenterology, Cilt: 16 - Sayı: 1, 29–33. https://ajindex.com/articles/410880

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Graham DY, Evans DG, Evans DJ Jr. Campylobacter pylori. The organism and its clinical relevance. J Clin Gastroenterol 1989; 11 (Suppl 1): S43-8
  2. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338; 1175-6
  3. Coghlan JG, Gilligan D, Humphries H, et al. Campylobacter pylori and recurrence of duodenal ulcers: a 12-month follow-up study. Lancet 1987 Nov 14; 2(8568): 1109-11
  4. Malfertheiner P, Megraud F, O'Morain C, et al. and the European Helicobacter Pylori Study Group (EPHSG). Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80
  5. Hunt RH. Eradication of H. pylori infection. Am J Med 1996; 100: 42-51
  6. Daw MA, Deegan P, Leen E, O’Morain C. Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. Aliment Pharmacol Ther 1991; 5: 435-9
  7. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pomp inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490-6
  8. Graham DY. Clarithromycin for treatment of H. pylori infection. Eur J Gastroenterol Hepatol 1995; 7 (Suppl 1): 55-8
  9. Leung WK, Graham DY. Clarithromycin for Helicobacter pylori infection. Expert Opin Pharmacother 2000; 1: 507-14
  10. Wolle K, Leodolter A, Malfertheiner P, et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51; 705-9
  11. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe. Clin Microbiol Infect 2002; 8: 388-96
  12. Sezgin O, Alt›ntafl E, Ulu O, et al. H. pylori eradikasyonunda üç farkl› proton pompas› inhibitörünün karfl›laflt›r›lmas› (Abstract). Turk J Gastroenterol 2002; 13 (Suppl 1): PB4/23
  13. Telaku S, Hatemi ‹, Erdamar S, et al. Helicobacter pylori eradikasyonunda 1 ve 2 haftal›k lansoprazole-amoxicillineclarithromycin protokollerinin karfl›laflt›r›lmas› (Abstract). Turk J Gastroenterol 2002; 13 (Suppl 1): PB4/46
  14. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 16: 1311-5
  15. Graham DY, Opekun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993; 16: 292-4
  16. Al-Assi MT, Ge